Identifying New Drugs to Fight SARS-CoV-2
Author Information
Author(s): Tonelli Michele, Sparatore Anna, Bassanini Ivan, Francesconi Valeria, Sparatore Fabio, Maina Kevin K., Delbue Serena, D’Alessandro Sarah, Parapini Silvia, Basilico Nicoletta
Primary Institution: Università degli Studi di Milano
Hypothesis
Can structurally distinct chemotypes inhibit SARS-CoV-2 replication?
Conclusion
Several compounds showed antiviral activity against SARS-CoV-2 and may be promising candidates for further development.
Supporting Evidence
- Compounds 10 and 11 were more potent than chloroquine.
- Six compounds exhibited a selectivity index indicating promising antiviral activity.
- Compounds 2 and 3 showed the best IC50 values of 1.5 and 4.0 µM.
Takeaway
Researchers tested 25 different compounds to see if they could stop the virus that causes COVID-19, and some of them worked pretty well.
Methodology
Twenty-five compounds were evaluated in vitro for cytotoxicity against Vero E6 cells and their ability to inhibit SARS-CoV-2 replication.
Limitations
The study primarily focused on in vitro results, which may not fully translate to in vivo efficacy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website